{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-XPKS8GCE/4b86553f-a7a6-4b58-ab30-7b355cac0eba/HTML","dcterms:extent":"25 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-XPKS8GCE/beb0b307-fc36-48d4-b36a-650e28de8df6/PDF","dcterms:extent":"116 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-XPKS8GCE/53643bf7-3e93-4c85-8bce-665b48051d48/TEXT","dcterms:extent":"36 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-XPKS8GCE","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2005","dc:creator":"Kerec, Mojca","dc:format":[{"@xml:lang":"sl","#text":"številka:1"},{"@xml:lang":"sl","#text":"letnik:56"},{"@xml:lang":"sl","#text":"8 strani"},{"@xml:lang":"sl","#text":"str. 3-10"}],"dc:identifier":["ISSN:0014-8229","COBISSID:1722737","URN:URN:NBN:SI:doc-XPKS8GCE"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"citokromi"},{"@xml:lang":"sl","#text":"farmakodinamika"},{"@xml:lang":"sl","#text":"farmakokientika"},{"@xml:lang":"sl","#text":"interakcije"},{"@xml:lang":"sl","#text":"zaviralci kalcijevih kanalčkov"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Interakcije zdravil: zaviralci kalcijevih kanalčkov|"},"dc:description":[{"@xml:lang":"sl","#text":"Calcium channel blockers are used in the treatment of cardiovasculardisorders. Amlodipine, diltiazem, nifedipine in verapamil are the most often prescribed calcium channel blockers in outpatients settings inSlovenia. Several interactions are described in the literature between calcium channel blockers and other drugs. The mechanism of these interactions can be either pharmacokinetic or pharmacodynamic. However, pharmacokinetic interactions based on drug metabolism occur most often. Amlodipine, diltiazem,nifedipine in verapamil are all metabolized by cytochrome CYP3A4, whose activity can be inhibited or induced by several other drugs. Diltiazem, nifedipine in verapamil have marked first-pass metabolism. Therefore, altered activity of CYP3A4 can strongly influence their plasma concentrations and consequently also their therapeutic effects and occurrence of adverse effects.Moreover, verapamil in diltiazem are known inhibitors of CYP3A4, whichinfluences the drugs metabolized by this enzyme. The mechanism and the clinical outcomes of drug interactions as well as the management possibilitiesare described in this article"},{"@xml:lang":"sl","#text":"Zaviralci kalcijevih kanalčkov so učinkovine, ki se uporabljajo za zdravljenje bolezni srca in ožilja. Amlodipin, diltiazem, nifedipin in verapamil so najpogosteje ambulantno predpisani zaviralci kalcijevih kanalčkov Sloveniji. V literaturi je opisanih kar nekaj interakcij teh učinkovin z drugimi učinkovinami, pri čemer so interakcije glede na mehanizem lahko farmakokinetične ali farmakodinamične. Prevladujejo farmakokinetične interakcije na osnovi metabolizma. Amlodipin, diltiazem, nifedipin in verapamil se metabolizirajo s pomočjo citokroma CYP3A4, katerega aktivnost inhibirajo ali inducirajo številne druge učinkovine. Ker je za diltiazem, nifedipin in verapamil značilen izrazit predsistemski metabolizem, lahko spremenjena aktivnost CYP3A4 močno spremeni plazemske koncentracije teh učinkovin in s tem tudi njihove terapevtske učinke ter pojav neželenih učinkov. Poleg tega sta verapamil in diltiazem tudi inhibitorja CYP3A4, kar vpliva na plazemske koncentracije učinkovin, ki se metabolizirajo s tem encimom. V prispevku so poleg mehanizmov in kliničnih učinkov posameznih interakcij opisane tudi možnosti za ukrepanje"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-XPKS8GCE","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-XPKS8GCE"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-XPKS8GCE/beb0b307-fc36-48d4-b36a-650e28de8df6/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-XPKS8GCE/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-XPKS8GCE"}}}}